Lundbeck
6 Parkway North
Deerfield
Illinois
60015
United States
Tel: 224-507-1000
Website: https://www.lundbeck.com/global
About Lundbeck
At Lundbeck, we are tirelessly dedicated to restoring brain health so every person can be their best. Headquartered in Copenhagen with a U.S. home office in Deerfield, Ill., Lundbeck is the only global biopharmaceutical company focused solely on brain diseases. Our legacy in neuroscience goes back seven decades and we have a long heritage of innovation. Lundbeck has developed and commercialized some of the world’s most widely prescribed therapies for psychiatric and neurological disorders. Today, we remain uncompromisingly committed to improving the quality of life for people impacted by brain disorders. Lundbeck is unique from other biopharmaceutical companies in that we are 70 percent owned by a research-focused foundation. We have a deep and productive pipeline, and we continue to bring forward symptomatic therapies to help people live better lives, while simultaneously pursuing disease-modifying treatments.
Offices in:
- Deerfield, IL - Lundbeck US Home Office
- LaJolla, CA - Lundbeck La Jolla Research Center, Inc.
- Bothell, WA - Lundbeck Seattle BioPharmaceuticals, Inc
Diversity matters, and inclusion creates powerful organizations To ensure that we reflect the diversity of our patients and their needs, we are focused on creating the context, culture, and systems where all Lundbeck employees - no matter who and where they are - can be their authentic self and perform at their best. In practice, this means that individuals feel empowered not despite their differences but because of them. We know that people are sometimes put into boxes - some of these boxes are of our own choosing and some of these boxes are chosen for us. For this reason, Lundbeck is taking a systematic, business-led approach to D&I that looks into and breaks down these boxes. Our bold action on inclusion includes an ambitious two-year plan that enables equality of opportunity through fairness and transparency, promotes openness, tackles bias and discrimination, and fosters belonging through our unique Lundbeck culture. From the highest levels of Lundbeck to the shop floor, we are working to ensure D&I is an integrated practice and mindset. "We win together. Lundbeck is a place where you grow and thrive – personally and professionally. We embrace the uniqueness of individuals, knowing we are stronger when every brain is in the game." Deborah Dunsire, CEO
Benefits
Lundbeck offers a competitive benefits package that includes:
• Medical, dental, vision effective day 1 of employment
• Generous vacation, sick leave, holiday shut down and company paid holidays
• 401k match with immediate vesting
• Parental Leave
• Hybrid work model for office-based roles
To view more details about our Benefits, please click on the link below.
Lundbeck 2023 Benefits Summary
Sustainable Development Goals
In 2020, we based the key aspects of our sustainability strategy on the UN Sustainable Development Goals (SDGs). We found we have a significant impact on seven of the 17 Goals:
• Goal 3: Good Health and Well-being
• Goal 5: Gender Equality
• Goal 8: Decent Work and Economic Growth
• Goal 10: Reduced Inequalities
• Goal 12: Responsible Consumption and Production
• Goal 13: Climate Action
• Goal 16: Peace, Justice, and Strong Institutions
Key examples are Goal 3 that is closely linked to our corporate purpose and dedication to restore brain health and Goal 13 that drives our efforts to prepare for a zero emissions future. We will use our influence and act to promote Goals 5, 8, 12 and 16. Across our sustainability actions, we are seeking partnerships with others to enable change and maximize impact (Goal 17).
Who We Are
A highly specialized pharmaceutical company that has conducted neuroscience research for more than 70 years. We develop innovative treatments to restore brain health and transform the lives of millions of people worldwide.
What We Strive For
Global leadership in brain health. Whatever your area of specialization, you will be part of our company-wide commitment to develop and advance treatments that improve the lives of people with brain disease.
What Drives Us
A culture of innovation, collaboration, and respect. We inspire curiosity, expect integrity, and pursue our achievements through knowledge-sharing, patient engagement, and the passion to deliver our end goal.
Our Societal Commitment
We understand we carry a huge responsibility for the societies we serve, and use our knowledge and voice to raise awareness, challenge standards, and increase opportunities – for patients and each other. We are at the forefront of treatment innovation, and together we continue to make a difference to people living with brain diseases.
Our Investment in You
As one way we invest in your career, we offer our employees a competitive compensation and benefit package that matches benchmark and general market conditions in our individual business locations.
Employee Satisfaction
The success of our strategy, “Expand and Invest to Grow Lundbeck” hinges on our combined competencies – and competence hinges on highly qualified and motivated employees. Our Employee Satisfaction Survey (ESS) gives us the pulse on employee motivation by asking about key elements in our work lives including management, work climate and development opportunities. We follow up on the ESS with concrete initiatives aimed at maintaining our focus on our unique workplace culture and providing personalized and aligned development opportunities for our employees.
Our Beliefs
• Patient-driven We put patients at the center of our fight for health and human dignity.
• Courageous We dare to confront unsolved healthcare challenges.
• Ambitious We set high expectations for ourselves because people in need have high expectations of us.
• Passionate We persist in developing life-changing therapies because life should not be interrupted by brain disease.
• Responsible We act with respect and integrity in everything we do
CONNECT
Every Brain in the Game
207 articles about Lundbeck
-
Genmab A/S Reaches Fourth Milestone in Lundbeck Inc. Collaboration
12/6/2013
-
Lundbeck Inc. Appoints Senior Vice President For Business Development And HR
12/3/2013
-
Lundbeck Inc. Increases Its Share Capital By 39,549 Shares (0,02016% Of Outstanding Shares) As A Result Of Employee Warrant Exercise
11/19/2013
-
Lundbeck Inc. Launches Fourth Annual Build Hope For Huntington’s Disease Campaign In Partnership With The Hereditary Disease Foundation
11/12/2013
-
Lundbeck Inc. and Otsuka Pharmaceutical Co., Ltd. Take Alcohol Drug to Japan in $136 Million+ Pact
10/31/2013
-
Lundbeck Inc.'s Epilepsy Drug for Children SABRIL® Grabs FDA Approval
10/29/2013
-
Actelion Ltd. and Lundbeck Inc. Get Positive CHMP Opinions
10/28/2013
-
Lundbeck Inc. Research Projects Secure Funding From The Michael J. Fox Foundation
10/14/2013
-
Lundbeck Inc. and Otsuka Pharmaceutical Co., Ltd. Initiate Phase 3 Clinical Trials on Lu AE58054 as a New Add-on Treatment for Alzheimer's Disease
10/10/2013
-
Upsher-Smith Laboratories Announces Development Agreement With Lundbeck Inc.
10/1/2013
-
Lundbeck Inc., Takeda Pharmaceutical Co. Ltd.'s Win FDA Approval for Depression Drug
10/1/2013
-
Lundbeck Inc. Reorganization to Affect Up to 200 Staffers
9/30/2013
-
Lundbeck Inc. Launches Selincro® in Denmark
9/30/2013
-
Otsuka Pharmaceutical Co., Ltd. and Lundbeck Inc. Receive Positive CHMP Opinion in Europe for Abilify Maintena, a Once-Monthly Injectable for Schizophrenia
9/20/2013
-
Lundbeck Inc. Epilepsy Research Featured in Report on Neurological Disorders
8/30/2013
-
Lundbeck Inc. Release: ONFI® (clobazam) CIV Scored Tablets and Oral Suspension Now Available in U.S. Pharmacies
8/12/2013
-
Lundbeck Inc. to Hire More Than 200 Reps to Market Brintellix
8/8/2013
-
New Products Up 48%, Lundbeck Inc. Raises Expectations for 2013
8/7/2013
-
Lundbeck Inc. and Otsuka Pharmaceutical Co., Ltd. Release: Phase II Clinical Data Show Statistically Sgnificant Improvement for Lu AE58054 as Addon to Donepezil, Versus donepezil Alone, on Cognitive Symptoms of Alzheimer's Disease
7/17/2013
-
EU to Fine Lundbeck Inc., Others for Blocking Generic Drugs
6/4/2013